Found 660 clinical trials
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
- 0 views
- 19 Feb, 2024
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …
- 0 views
- 19 Feb, 2024
S0820, Adenoma and Second Primary Prevention Trial (PACES)
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing the event rate of adenomas and second primary colorectal cancers at three years in patients previously treated for stage 0 to III colon or rectal cancer.
- 0 views
- 02 Dec, 2024
- 1 location
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study
Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells
- 0 views
- 19 Feb, 2024
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers. ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - …
- 0 views
- 19 Feb, 2024
PTX-35 in Patients With Advanced Solid Tumors
A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care
- 0 views
- 19 Feb, 2024
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
The 4SCAR-CD276-modified T cells (4SCAR-276) can recognize and kill tumor cells through the recognition of CD276, a surface protein expressed at high levels on many types of tumors but at low levels on normal tissues.
- 0 views
- 19 Feb, 2024
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer
This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers.
- 0 views
- 19 Feb, 2024
4SCAR-T Therapy Post CD19-targeted Immunotherapy
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized …
- 0 views
- 19 Feb, 2024
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
This study is a multi-center, open-label, dose escalation study of RLY-1971 in subjects with advanced or metastatic solid tumors.
- 0 views
- 19 Feb, 2024